| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-09-07 | Cell Therapy Catapult (UK) TrakCel (UK) | needle-to-needle supply chain management platform | collaboration | Technology - Services | Collaboration agreement | |
| 2017-09-07 | Eli Lilly (USA - IN) | restructuring | Restructuring | |||
| 2017-09-07 | Abivax (France) Evotec (Germany) | small molecules for the treatment of multiple serious viral infectious diseases | viral infectious diseases | development | Infectious diseases | Development agreement |
| 2017-09-07 | Iovance Biotherapeutics (US - CA) The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) (USA - OH) | tumor-infiltrating lymphocyte (TIL), marrow-infiltrating lymphocyte (MIL) and peripheral blood-associated lymphocyte technologies | hematologic malignancies including acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). | research - R&D | Cancer - Oncology | Research agreement |
| 2017-09-06 | OSE Immunotherapeutics (France) GERCOR (France) | Tedopi® | locally advanced or metastatic pancreatic cancer | clinical research | Cancer - Oncology - Rare diseases | Clinical research agreement |
| 2017-09-06 | Bioverativ (USA - MA) Bicycle Therapeutics (USA - MA) | Bicycles | hemophilia, sickle cell disease | research - development - R&D | Rare diseases - Genetic diseases - Hematological diseases | Research agreement |
| 2017-09-06 | BioNTech (Germany) Cellscript (USA - WI) | nucleoside-modified messenger RNA (mRNA) | licensing | Technology - Services | Licensing agreement | |
| 2017-09-05 | Boehringer Ingelheim (Germany) Inventiva (France) | new medicines for the treatment of idiopathic pulmonary fibrosis | idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases | research - R&D - licensing | Lung diseases - Respiratory diseases - Rare diseases - Fibrotic diseases | Exercise of an option agreement |
| 2017-09-05 | Portola Pharmaceuticals (USA - CA) Lonza (Switzerland) | AndexXa®(US)/ IndexXa™ (EU) | production - manufacturing | Production agreement | ||
| 2017-09-05 | TiGenix (Belgium) | manufacturing facility in Madrid | validation of a production plant | Autoimmune diseases - Inflammatory diseases | Validation of a production plant | |
| 2017-09-05 | Retrotope (USA - CA) National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS) (USA) NGLY1.org (USA - UT) | small molecule therapeutics for NGLY1 deficiency | NGLY1 deficiency | research | Rare diseases - Genetic diseases - Neurodevelopmental diseases | Research agreement |
| 2017-09-04 | Novartis (Switzerland) | resignation - nomination | Nomination | |||
| 2017-09-04 | Abbvie (USA - IL) Inventiva (France) | ROR-gamma inverse agonists | research - development | Research agreement | ||
| 2017-09-04 | Eyevensys (France) | chief medical officer | nomination | Ophtalmological diseases | Nomination | |
| 2017-09-01 | Oncurious (Belgium) VIB (Belgium) | immuno-oncology assets | product acquisition | Cancer - Oncology | Product acquisition | |
| 2017-08-31 | Macrogenics (USA - MD) Janssen Biotech, a J&J company (USA - NJ) | MGD015 (JNJ-9383) | hematological cancers, solid tumors | Cancer - Oncology | Licensing agreement | |
| 2017-08-31 | Nabriva Therapeutics (Ireland) | chief medical officer | resignation | Infectious diseases | Resignation | |
| 2017-08-31 | BeiGene (China) Celgene (USA - NJ) | BGB-A317, Celgene's approved therapies in China (Abraxane®, Revlimid®, Vidaza®) and pipeline agent CC-122 | solid tumors | development - commercialisation | Cancer - Oncology | Development agreement |
| 2017-08-30 | Roche (Switzerland) Pharmstandard (Russia) | Gaziva® (obinutuzumab) | bioproduction - manufacturing | Cancer - Oncology | Production agreement | |
| 2017-08-29 | Boston Pharmaceuticals (USA - MA) Daiichi Sankyo (Japan) | DS-5010 | licensing | Cancer - Oncology | Licensing agreement |
